Shinpei Hashimoto
Papers
1
Total Citations
7
H-Index
1
About
Shinpei Hashimoto is a leading figure in radiation oncology, with a focused expertise in hypofractionated radiotherapy for prostate cancer. His research centers on optimizing treatment delivery and minimizing toxicity, particularly through the use of advanced non-isocentric robotic radiosurgery systems. Hashimoto’s major contribution lies in demonstrating the feasibility and safety of extremely hypofractionated radiotherapy (EHF-RT) for early-stage prostate cancer. His pivotal 2016 study, which has garnered 7 citations, systematically evaluated rectal toxicity in patients treated with this ultra-precise approach, providing critical data that supports shorter, more convenient treatment regimens without compromising patient safety. By rigorously analyzing dose-volume effects and clinical outcomes, Hashimoto has helped refine protocols that reduce gastrointestinal side effects, a key concern in prostate cancer management. His work bridges the gap between technological innovation and practical clinical application, offering a model for integrating robotic radiosurgery into standard care. For students and researchers, Hashimoto’s research exemplifies how targeted dosimetric analysis can transform radiotherapy, making it both more effective and more tolerable.
Research Focus
Key Achievements
Top Papers
- 1